GeoVax Labs received approximately $3,646,482 from the cash exercise of warrants covering 5,697,628 common shares and issued new warrants for up to 11,395,256 shares at $0.64 each. For investors, the transaction provides gross proceeds while creating additional Warrant rights that require stockholder approval before exercise.

Key Highlights

  • The new warrants carry a $0.64-per-share exercise price and become exercisable after required Nasdaq stockholder approval.
  • GeoVax Labs agreed to reimburse A.G.P./Alliance Global Partners up to $40,000 for accountable legal expenses.
  • The warrant exercise covered 5,697,628 common shares and generated approximately $3,646,482 in gross proceeds.

Transaction Overview

GeoVax Labs, Inc. (NASDAQ: GOVX) received approximately $3,646,482 in gross proceeds after a holder exercised warrants for 5,697,628 common shares. The transaction also resulted in GeoVax issuing warrants covering up to 11,395,256 additional common shares.

The proceeds described in the transaction are gross proceeds, and the company agreed to compensate its exclusive financial adviser separately through a cash payment based on those proceeds and reimbursement of certain accountable legal expenses. The warrant exercise and the issuance of the new warrants are the central components of the transaction described by GeoVax.

Exercised Warrants

The exercised warrants were issued across February 17, March 31, May 8 and May 19, 2026. Those warrants had current exercise prices of $2.31, $1.36, $1.65 and $1.48 per share, respectively.

The four issuance dates correspond to the four exercise prices identified in the transaction description. Together, the exercised warrants covered the 5,697,628 common shares that were issued in connection with the approximately $3,646,482 in gross proceeds received by GeoVax.

New Warrant Issuance

In return for the warrant exercise, GeoVax issued new warrants covering up to 11,395,256 additional shares. The new warrants were issued on August 26, 2026, and are substantially similar to the warrants that were exercised.

The new warrants therefore form part of the consideration associated with the holder’s exercise of the existing warrants. The article identifies the number of additional shares covered by the new warrants, while describing their terms generally through their substantial similarity to the exercised warrants.

Exercise Conditions

Exercise of the new warrants can begin after any stockholder approval required under Nasdaq rules. This means that the timing for beginning exercise is tied to the completion of any approval process that Nasdaq rules may require. It states only that exercise may commence after the applicable stockholder approval, if one is required under Nasdaq rules.

Securities Law Status

The new warrants were issued under Regulation D. The new warrants and the shares issuable upon their exercise were not registered under the Securities Act. Accordingly, the transaction description identifies both the exemption framework used for the warrant issuance and the registration status of the securities involved.

Financial Adviser

A.G.P./Alliance Global Partners served as GeoVax’s exclusive financial adviser for the transaction. GeoVax agreed to pay the adviser 7.0% of gross proceeds in cash.

GeoVax also agreed to reimburse up to $40,000 in accountable legal expenses. These cash compensation and expense-reimbursement arrangements were part of the terms agreed with A.G.P./Alliance Global Partners in connection with the transaction.

Peers Moving on This News